Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb 13;21(1):98-108.
doi: 10.2119/molmed.2015.00033.

Cysteine Oxidation Targets Peroxiredoxins 1 and 2 for Exosomal Release through a Novel Mechanism of Redox-Dependent Secretion

Affiliations

Cysteine Oxidation Targets Peroxiredoxins 1 and 2 for Exosomal Release through a Novel Mechanism of Redox-Dependent Secretion

Lisa Mullen et al. Mol Med. .

Abstract

Nonclassical protein secretion is of major importance as a number of cytokines and inflammatory mediators are secreted via this route. Current evidence indicates that there are several mechanistically distinct methods of nonclassical secretion. We have shown recently that peroxiredoxin (Prdx) 1 and Prdx2 are released by various cells upon exposure to inflammatory stimuli such as lipopolysaccharide (LPS) or tumor necrosis factor alpha (TNF-α). The released Prdx then acts to induce production of inflammatory cytokines. However, Prdx1 and 2 do not have signal peptides and therefore must be secreted by alternative mechanisms, as has been postulated for the inflammatory mediators interleukin-1β (IL-1β) and high mobility group box-1 (HMGB1). We show here that circulating Prdx1 and 2 are present exclusively as disulfide-linked homodimers. Inflammatory stimuli also induce in vitro release of Prdx1 and 2 as disulfide-linked homodimers. Mutation of cysteines Cys51 or Cys172 (but not Cys70) in Prdx2, and Cys52 or Cys173 (but not Cys71 or Cys83) in Prdx1 prevented dimer formation and this was associated with inhibition of their TNF-α-induced release. Thus, the presence and oxidation of key cysteine residues in these proteins are a prerequisite for their secretion in response to TNF-α, and this release can be induced with an oxidant. By contrast, the secretion of the nuclear-associated danger signal HMGB1 is independent of cysteine oxidation, as shown by experiments with a cysteine-free HMGB1 mutant. Release of Prdx1 and 2 is not prevented by inhibitors of the classical secretory pathway, instead, both Prdx1 and 2 are released in exosomes from both human embryonic kidney (HEK) cells and monocytic cells. Serum Prdx1 and 2 also are associated with the exosomes. These results describe a novel pathway of protein secretion mediated by cysteine oxidation that underlines the importance of redox-dependent signaling mechanisms in inflammation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Endogenous (E) and recombinant (R) Prdx2 are released from HEK 293T cells in response to treatment with TNF-α. (A) Time course of Prdx2 release in response to treatment with TNF-α analyzed by Western blotting following nonreducing SDS-PAGE of conditioned media from 293T cells expressing recombinant Prdx2 using anti-Prdx2 antibody. The two arrows indicate rPrdx2 (upper band), which is larger due to V5, and His tags and endogenous Prdx2 (lower band). (B) Intracellular and extracellular levels of endogenous (E) and recombinant (R) Prdx2 in HEK 293T cells ± TNF-α treatment for 24 h (left, gel run under nonreducing conditions; right, reducing). The dimeric form disappears under reducing conditions. (C) Release of endogenous and recombinant Prdx2 from HEK 293T cells 24 h after menadione treatment.
Figure 2
Figure 2
Cell toxicity does not account for the Prdx2 observed in HEK 293T cell culture supernatants. (A) Cell viability measured by CellTiter-Glo assay 24 h after treatment with 50 ng/mL TNF-α or varying concentrations of menadione. ** p < 0.0001; *p < 0.02, versus control by Dunnett test with one-way analysis of variance (ANOVA). (B) Sensitivity of the CellTiter-Glo assay demonstrated by plating varying numbers of 293T cells. *p < 0.005 versus control. (C) Western blot analysis of actin in the supernatants or (D) cell lysates from 293T cells.
Figure 3
Figure 3
Release of other Prdx proteins from HEK 293T cells. (A) Release of endogenous (E) and recombinant (R) Prdx1 in response to treatment with TNF-α analyzed by Western blotting following nonreducing SDS-PAGE. Intracellular expression of Prdx1 consists of both monomers and dimers and DTT treatment results in the disappearance of the dimeric form. (B) and (C). Absence of Prdx4 (B) and Prdx5 (C) in the conditioned media of HEK 293T cells ± TNF-α. Both proteins (indicated by arrows) were detected in cell lysates by Western blotting following nonreducing SDS-PAGE with anti-Prdx4 and anti-Prdx5 respectively.
Figure 4
Figure 4
Purified recombinant Prdx2 does not form dimers in HEK 293T cell culture. (A) Recombinant Prdx2 consists of monomer and dimer, which can be reduced to monomer by treatment with DTT. Removal of DTT results in reversion to a mixture of monomers and dimers. (B) Incubation of recombinant Prdx2 (shown by arrow in panel A) with HEK 293T cell for 24 h does not result in oxidation of monomer to dimer.
Figure 5
Figure 5
Mutation of cysteines involved in disulfide bond formation prevents release of Prdx1 and Prdx2 from HEK 293T cells. (A) Catalytic mechanism of Prdx2. The peroxidatic cysteine C51 (C52 in Prdx1) reacts with peroxide then with the resolving cysteine C172 (C173 in Prdx1) on the second subunit of the dimer to form disulfide bonds. (B) Prdx1 and (C) Prdx2 cysteine mutants. Intracellular expression of recombinant wild-type and mutated Prdx1 (D) and Prdx2 (E) in HEK 293T cell lysates analyzed by Western blotting with anti-V5 or anti-His antibody, respectively, following nonreducing SDS-PAGE to allow identification of monomers and dimers. Release of Prdx1 (F) and Prdx2 (G) also were analyzed by Western blotting of conditioned media from HEK 293T cells ± TNF-α using specific antibodies following nonreducing SDS-PAGE.
Figure 6
Figure 6
Mutation of cysteine residues does not prevent release of HMGB-1 from HEK 293T cells. (A) Intracellular expression of recombinant wild-type and mutated HMGB-1 in HEK 293T cell lysates analyzed by Western blotting with anti-V5 antibody following reducing SDS-PAGE. Cell lysates were diluted 50-fold before applying to gel. (B) Release of HMGB-1 from HEK 293T cells analyzed by Western blotting of conditioned media applied to gel without dilution using anti-V5 antibody following reducing SDS-PAGE. (C) Densitometric analysis of released HMGB-1 expressed as a percentage of intracellular HMGB-1.
Figure 7
Figure 7
Both Prdx1 and Prdx2 are associated with exosomes in cell culture supernatants and in healthy human serum. Western blot analysis of (A,C) Prdx1 or (B,D) Prdx2 present in exosomal or cytosolic fractions of supernatants from (A,B) HEK 293T cells or from (C,D) THP-1 cells. Blots were stripped and reprobed with anti-HSP70 antibody to confirm the presence of exosomes. (E) Western blotting of human serum from four healthy donors using anti-Prdx2 following nonreducing SDS-PAGE. Addition of DTT reduces the dimers to monomers. (F) Exosomes were prepared from serum samples by ultracentrifugation and analyzed by Western blotting with anti-Prdx2 in nonreducing and reducing conditions.
Figure 8
Figure 8
Schematic model of redox-regulated release of Prdx 1 and 2. Oxidized Prdx 1 and 2 are targeted to exosomes for release following exposure of the cells to inflammatory agents or oxidants.

References

    1. Rhee SG, et al. Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Curr Opin Cell Biol. 2005;17:183–9. - PubMed
    1. Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH. 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol Med. 2005;11:571–8. - PMC - PubMed
    1. Chang JW, et al. Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett. 2005;579:2873–7. - PubMed
    1. Gharib SA, et al. Of mice and men: comparative proteomics of bronchoalveolar fluid. Eur Respir J. 2010;35:1388–95. - PMC - PubMed
    1. Gerrits EG, et al. Serum peroxiredoxin 4: a marker of oxidative stress associated with mortality in type 2 diabetes (ZODIAC-28) PLoS One. 2014;9:e89719. - PMC - PubMed

Publication types